Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Dapagliflozin

Tablet and IV solution, Oral and IV, 10 mg po and 100 µg IV, Single oral dose followed by a single IV dose (IV dose administered at 1h after oral dose), 1 day

Trial Locations (1)

53704

Covance Clinical Research Unit, Inc., Madison

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

AstraZeneca

INDUSTRY